Drug Search Results
More Filters [+]

ANX-188

Alternative Names: anx-188, anx188, anx 188
Latest Update: 2015-05-20
Latest Update Note: Clinical Trial Update

Product Description

ANX-188 adheres specifically to hydrophobic surfaces characteristic of damaged cells in the circulation, effectively ‘sealing’ the damaged area and, as a result, minimizing or preventing other hydrophobic adhesive interactions and providing time for natural repair mechanisms to restore normal functioning.  (Sourced from: https://www.sec.gov/Archives/edgar/data/1160308/000129993313000384/exhibit1.htm)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Savara
Company Location: AUSTIN TX 78746
Company CEO: Matthew Pauls
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ANX-188

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ANX-188-05

P1

Completed

Healthy Volunteers

2013-04-01

Recent News Events

Date

Type

Title